Product Description: Mibefradil (Ro 40-5967) is a calcium channel blocker with moderate selectivity for T-type Ca2+ channels displaying IC50s of 2.7 μM and 18.6 μM for T-type and L-type currents, respectively[1].
Applications: Neuroscience-Neuromodulation
Formula: C29H38FN3O3
Citations: Biochem Biophys Res Commun. 2020 Feb 19;522(4):862-868./Br J Pharmacol. 2021 Jan;178(2):346-362./Eur J Pharmacol. 2021 Feb 5;892:173782./Front Pharmacol. 23 February 2022./J Cell Physiol. 2021 Mar 11./Mediat Inflamm. 2020 Nov 10;2020:3691701./Theriogenology. 2021 Jan 1;159:140-146./ACS Nano. 2024 Oct 31./Front Pharmacol. 2022 Feb 23;13:816133./PLoS Biol. 2024 Mar 25;22(3):e3002565./Res Sq. 2024 Jun 11./Small. 2024 Aug 10:e2403381.
References: [1]Mehrke G, et al. The Ca(++)-channel blocker Ro 40-5967 blocks differently T-type and L-type Ca++ channels. J Pharmacol Exp Ther. 1994 Dec;271(3):1483-8./[2]Brain KL, et al. The sources and sequestration of Ca(2+) contributing to neuroeffector Ca(2+) transients in the mouse vas deferens. J Physiol. 2003 Dec 1;553(Pt 2):627-35./[3]Yu YF, et al. Protection of the cochlear hair cells in adult C57BL/6J mice by T-type calcium channel blockers. Exp Ther Med. 2016 Mar;11(3):1039-1044./[4]Shiue SJ, et al. Chronic intrathecal infusion of T-type calcium channel blockers attenuates CaV3.2 upregulation in nerve-ligated rats. Acta Anaesthesiol Taiwan. 2016 Oct 17. pii: S1875-4597(16)30071-6.
CAS Number: 116644-53-2
Molecular Weight: 495.63
Research Area: Cardiovascular Disease; Cancer
Solubility: 10 mM in DMSO
Target: Calcium Channel
English
Deutsch
